37.17
Zai Lab Limited Adr stock is traded at $37.17, with a volume of 635.73K.
It is down -1.59% in the last 24 hours and up +0.57% over the past month.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
See More
Previous Close:
$37.77
Open:
$36.8
24h Volume:
635.73K
Relative Volume:
0.73
Market Cap:
$4.13B
Revenue:
$418.33M
Net Income/Loss:
$-252.07M
P/E Ratio:
-15.49
EPS:
-2.4
Net Cash Flow:
$-238.84M
1W Performance:
+10.72%
1M Performance:
+0.57%
6M Performance:
+41.49%
1Y Performance:
+96.98%
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Name
Zai Lab Limited Adr
Sector
Industry
Phone
862161632588
Address
4560 JINKE ROAD, SHANGHAI
Compare ZLAB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ZLAB
Zai Lab Limited Adr
|
37.17 | 4.17B | 418.33M | -252.07M | -238.84M | -2.40 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
Mar-03-25 | Downgrade | BofA Securities | Buy → Neutral |
Dec-14-23 | Initiated | Morgan Stanley | Overweight |
Aug-10-23 | Initiated | Cantor Fitzgerald | Overweight |
Jan-21-22 | Initiated | Macquarie | Outperform |
Oct-12-21 | Initiated | Bernstein | Mkt Perform |
Apr-28-20 | Initiated | Goldman | Buy |
Apr-15-20 | Initiated | Guggenheim | Buy |
Jul-12-19 | Initiated | BofA/Merrill | Buy |
Jul-05-19 | Initiated | Macquarie | Outperform |
Jan-29-19 | Initiated | Credit Suisse | Outperform |
Nov-21-18 | Initiated | Jefferies | Buy |
Jun-21-18 | Resumed | Leerink Partners | Outperform |
Feb-14-18 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-16-17 | Initiated | JP Morgan | Neutral |
Oct-16-17 | Initiated | Leerink Partners | Outperform |
View All
Zai Lab Limited Adr Stock (ZLAB) Latest News
Cerity Partners LLC Makes New $420,000 Investment in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) - Defense World
Franklin FTSE Japan ETF (NYSEARCA:FLJP) Position Cut by Cerity Partners LLC - Defense World
Cerity Partners LLC Takes Position in KANZHUN LIMITED Sponsored ADR (NASDAQ:BZ) - Defense World
Cerity Partners LLC Purchases Shares of 19,622 Gold Fields Limited (NYSE:GFI) - Defense World
Envestnet Asset Management Inc. Raises Stock Position in First Trust Intermediate Government Opportunities ETF (NYSEARCA:MGOV) - Defense World
Zai Lab Limited's (NASDAQ:ZLAB) large institutional owners must be happy as stock continues to impress, up 4.9% over the past week - simplywall.st
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Shares Acquired by Envestnet Asset Management Inc. - Defense World
Knorr-Bremse (KNRRY) Expected to Announce Quarterly Earnings on Thursday - Defense World
Ero Copper (ERO) Expected to Announce Quarterly Earnings on Thursday - Defense World
Standard Chartered (SCBFY) Projected to Post Earnings on Thursday - Defense World
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities - Benzinga
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities16.07.25News - Ariva
M&T Bank Corp Reduces Stock Holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) - Defense World
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025 - Business Wire
Leerink Partnrs Issues Positive Outlook for Zai Lab Earnings - Defense World
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer - Business Wire
Cantor Fitzgerald Expects Reduced Earnings for Zai Lab - Defense World
Zai Lab (ZLAB) Delivers Positive ZL-1503 Trial Results in Treatment of Atopic Dermatitis - Yahoo Finance
Metric Deep Dive: Understanding Winnebago Industries, Inc (WGO) Through its Ratios - DWinneX
Zai Lab Limited ADR (ZLAB) Stock: A Year of Stock Market Dynamics - investchronicle.com
10 Biotech Stocks Screaming a Buy - Insider Monkey
Revenues Not Telling The Story For Zai Lab Limited (NASDAQ:ZLAB) After Shares Rise 33% - simplywall.st
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 - Business Wire
Zai Lab Limited ADR (ZLAB) Stock: Uncovering 52-Week Market Trends - investchronicle.com
CarParts.com Inc (PRTS) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Yatsen And Zai Lab Shine As Asian ADRs Climb In The US - Finimize
Zai Lab Limited (NASDAQ:ZLAB) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Two Sigma Investments LP Trims Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB) - Defense World
Two Sigma Advisers LP Boosts Stock Position in Zai Lab Limited (NASDAQ:ZLAB) - Defense World
Bank of America Corp DE Has $1.63 Million Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB) - Defense World
Insider Sell: Yajing Chen Sells 9,618 Shares of Zai Lab Ltd (ZLA - GuruFocus
Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)’s TTFields Therapy Succeeds in Phase 3 Trial - MSN
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Business Wire
Zai Lab Limited (NASDAQ:ZLAB) Sees Large Drop in Short Interest - Defense World
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Yahoo Finance
What Analysts Were Expecting After Zai Lab Limited ADR (NASDAQ: ZLAB) fell -3.74% - Stocksregister
Zai Lab Announces Participation in Investor Conferences in June 2025 - BioSpace
Zai Lab Lines Up Triple Conference Presence: Jefferies, Goldman Sachs, and Scotiabank Healthcare Events - Stock Titan
Upper Peninsula ABC 10News, Sports, Weather and More from Michigan's Upper Peninsula - FinancialContent
Northern Trust Corp Increases Holdings in Zai Lab Limited (NASDAQ:ZLAB) - Defense World
Quantinno Capital Management LP Reduces Position in Zai Lab Limited (NASDAQ:ZLAB) - Defense World
BNP Paribas Financial Markets Purchases 18,472 Shares of Zai Lab Limited (NASDAQ:ZLAB) - Defense World
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer - BioSpace
Barclays PLC Boosts Stake in Zai Lab Limited (NASDAQ:ZLAB) - Defense World
Cantor Fitzgerald Expects Increased Earnings for Zai Lab - Defense World
Zai Lab Limited (NASDAQ:ZLAB) Q1 2025 Earnings Call Transcript - Insider Monkey
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say - MSN
Decoding Zai Lab Ltd (ZLAB): A Strategic SWOT Insight - GuruFocus
Trading Day Triumph: Zai Lab Limited ADR (ZLAB) Ends at 29.38, a -5.07 Surge/Plunge - DWinneX
Raymond James Financial Inc. Makes New $1.03 Million Investment in Zai Lab Limited (NASDAQ:ZLAB) - Defense World
Zai Lab Limited (NASDAQ:ZLAB) Shares Bought by Invesco Ltd. - Defense World
Zai Lab Limited Adr Stock (ZLAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):